Anjan Nan
University of Maryland, Baltimore
35 Papers
591 Citations
Anjan Nan is an academic researcher from University of Maryland, Baltimore. The author has contributed to research in topics: Methacrylamide & N-(2-Hydroxypropyl) methacrylamide. The author has an hindex of 20, co-authored 35 publications. Previous affiliations of Anjan Nan include University of Maryland Marlene and Stewart Greenebaum Cancer Center & University of Mississippi.
Chat about Author
Papers
Cellular Uptake and Cytotoxicity of Silica Nanotubes
TL;DR: This work evaluates the influence of size and surface charge of SNTs on cellular toxicity and uptake and indicates endocytosis to be one possible mechanism of internalization of S NTs.
224
Targeting tumor angiogenic vasculature using polymer-RGD conjugates.
TL;DR: This construct provides a foundation that should support targeted delivery of radionuclides and drugs to solid tumors for diagnostic and therapeutic applications and suggest that specific tumor angiogenesis targeting is possible with HPMA copolymer-RGD4C conjugates.
164
Template synthesis of multifunctional nanotubes for controlled release.
TL;DR: The biomedical applications of nanot tubes will be discussed with emphasis on the template synthesis of composite nanotubes containing silica and iron oxide that have potential use in drug delivery, magnetic resonance imaging (MRI), and chemical and biochemical separations.
125
•Journal Article
Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates.
TL;DR: Specific molecular targeting of the alpha(v)beta(3) integrin and nonspecific vascular permeability are both significant in the relative tumor localization of polymeric conjugates of RGD4C.
121
Targetable water-soluble polymer-drug conjugates for the treatment of visceral leishmaniasis.
TL;DR: Targetable N-(2-hydroxypropyl)methacrylamide copolymer-anti-leishmanial drug conjugates for the treatment of visceral leishmaniasis and copolymers containing ManN in the side chains can potentially reduce the toxicity and increase efficacy of anti-leishingmanial drugs for thetreatment of VL.
74